[1]Wang CS, Greenbaum LA. Nephrotic syndrome[J]. Pediatr Clin North Am, 2019, 66:73-85. [2]Wang Z, Huang W, Li H, et al. Synergistic action of inflammation and lipid dysmetabolism on kidney damage in rats[J]. Ren Fail, 2018, 40:175-182. [3]Yin XN, Wang J, Cui LF, et al. Enhanced glycolysis in the process of renal fibrosis aggravated the development of chronic kidney disease[J]. Eur Rev Med Pharmacol Sci, 2018, 22:4243-4251 [4]Rayego-Mateos S, Rodrigues-Diez R, Morgado-Pascual JL, et al. Role of epidermal growth factor receptor (EGFR) and its ligands in kidney inflammation and damage[J]. Mediators Inflamm, 2018, 11:1-12. [5]李秋艳. 沙利度胺治疗肺间质纤维化的效果分析[J]. 中外女性健康研究, 2018, 10:108-109. [6]郭晓媛, 蔡月茹, 孙广宇, 等. 扶正祛风方对膜性肾病大鼠蛋白尿及肾脏病理改变的影响[J]. 中国实验方剂学杂志, 2018, 24:144-149. [7]卢华, 曹灵. 膜性肾病发病机制的研究进展[J]. 广东医学, 2019, 40:156-159. [8]崔昭, 张潇丹, 赵明辉. 日益增多的肾脏疾病:膜性肾病[J]. 中华内科杂志, 2020, 59:157-160. [9]李丹丹. 糖皮质激素联合沙利度胺治疗难治性膜性肾病临床效果[J]. 国际医药卫生导报, 2017, 23:1057-1059. [10]Sutariya B, Jhonsa D, Saraf MN. TGF-β: the connecting link between nephropathy and fibrosis[J]. Immunopharmacol Immunotoxicol, 2016, 38:39-49. [11]薛丕良, 李凤金, 白茹, 等. 参芪蛭龙汤对膜性肾病大鼠血清中IL-2、IL-6和TNF-α水平的影响[J]. 中医药信息, 2019, 36:8-12. [12]高宏宇, 王晔, 张莉, 等. 沙利度胺对膜性肾病及VEGF、PLA2R、TNF-α等因子的影响[J]. 临床药物治疗杂志, 2019, 17:70-73. [13]Overstreet JM, Wang Y, Wang X, et al. Selective activation of epidermal growth factor receptor in renal proximal tubule induces tubulointerstitial fibrosis[J]. FASEB J, 2017, 31:4407-4421. [14]叶文冲, 王瑞忠, 曾桐春, 等. 组分配伍四逆汤抑制ERK/cPLA2信号通路改善大鼠膜性肾病[J]. 药物评价研究, 2018, 41:91-95. |